 AUSTIN, TX and DURHAM, NC, March 11, 2021 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for poster presentation at the American Association for Cancer Research AACR Annual Meeting, which is being held virtually April 10-15, 2021. The first poster will highlight preclinical data from the companys GADLENTM platform, while the second will highlight preclinical data from the development of an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258 TIGIT-Fc-LIGHT, derived from the companys ARC platform, in an acquired resistance setting. 